A biomarker and phase II study of GW572016 [lapatinib] in recurrent malignant glioma.

Trial Profile

A biomarker and phase II study of GW572016 [lapatinib] in recurrent malignant glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 23 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top